Kairos Pharma, Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KAPA research report →
Price Chart
About the company
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma.
- CEO
- John S. Yu
- IPO
- 2024
- Employees
- 4
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on KAPA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.32M
- P/E
- -1.07
- Fwd P/E
- 0.82
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 1.51
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -98.77%
- ROIC
- -143.93%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-5,572,000
- Net Income
- $-5,447,000-109.3%
- EPS
- $-0.30-30.4%
- OCF Growth
- +13.0%
- FCF Growth
- +13.0%
- 52W High
- $2.11
- 52W Low
- $0.27
- 50D MA
- $0.36
- 200D MA
- $0.59
- Beta
- 1.56
- RSI (14)
- 39
- Avg Volume
- 2.19M
No earnings-call transcripts are available for KAPA yet.
- Free Float
- 41.9%
- Shares Outstanding
- 21.41M
- Float Shares
- 8.97M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 131.83K | 0 |
| Two Sigma Advisers, LP | 15.14K | ▲ 15.14K |
Held by 6 ETFs
Biggest fund positions in KAPA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 25 | Bhowmick Neil | other | 171,756 |
| Oct 8, 25 | Bae Hyun W. | other | 19,084 |
| Sep 16, 25 | Bae Hyun W. | other | 10,000 |
| Oct 8, 25 | Murali Ramachandran | other | 152,672 |
| Oct 8, 25 | Keyoung Hansoo Michael | other | 19,084 |
| Sep 16, 25 | Keyoung Hansoo Michael | other | 10,000 |
| Oct 8, 25 | Singhvi Rahul | other | 19,084 |
| Oct 8, 25 | Samuelson Doug | other | 152,672 |
| Oct 8, 25 | Yu John S | other | 190,840 |
| Dec 10, 24 | Singhvi Rahul | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KAPA coverage
Recent articles, reports, and earnings notes.
No research on KAPA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KAPA report →Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
businesswire.com · Jul 22
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
newsfilecorp.com · Jul 15
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
businesswire.com · Jul 15
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
zacks.com · Jul 2
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
newsfilecorp.com · Jun 19
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
businesswire.com · Jun 4
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
businesswire.com · May 14
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
newsfilecorp.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.